JPH09500660A - 高緩和性単量体化合物及び多量体化合物 - Google Patents
高緩和性単量体化合物及び多量体化合物Info
- Publication number
- JPH09500660A JPH09500660A JP7529486A JP52948695A JPH09500660A JP H09500660 A JPH09500660 A JP H09500660A JP 7529486 A JP7529486 A JP 7529486A JP 52948695 A JP52948695 A JP 52948695A JP H09500660 A JPH09500660 A JP H09500660A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- metal
- chelate
- hydrogen
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 114
- 239000000178 monomer Substances 0.000 title description 12
- 230000002040 relaxant effect Effects 0.000 title description 2
- 229910052751 metal Inorganic materials 0.000 claims abstract description 68
- 239000002184 metal Substances 0.000 claims abstract description 68
- 239000013522 chelant Substances 0.000 claims abstract description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 51
- 239000001257 hydrogen Substances 0.000 claims abstract description 46
- 125000000524 functional group Chemical group 0.000 claims abstract description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 20
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 16
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 5
- 125000004429 atom Chemical group 0.000 claims description 43
- -1 2-hydroxy-3 , 1-Propanediyl Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 12
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229960000367 inositol Drugs 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000005291 magnetic effect Effects 0.000 claims description 7
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 4
- 229910000077 silane Inorganic materials 0.000 claims description 4
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000005630 sialyl group Chemical group 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 238000002059 diagnostic imaging Methods 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- 229940059947 gadolinium Drugs 0.000 claims 2
- DRNKIOIJTYLTSS-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CP(O)(O)=O)CCN(CC(O)=O)CC1 DRNKIOIJTYLTSS-UHFFFAOYSA-N 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 27
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 7
- 239000012216 imaging agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 83
- 229910001868 water Inorganic materials 0.000 description 74
- 239000000243 solution Substances 0.000 description 61
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 239000000203 mixture Substances 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229940126062 Compound A Drugs 0.000 description 17
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000000376 reactant Substances 0.000 description 13
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000000921 elemental analysis Methods 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 229910021645 metal ion Inorganic materials 0.000 description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 150000004696 coordination complex Chemical class 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000005298 paramagnetic effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002118 epoxides Chemical class 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 4
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 3
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 229910052776 Thorium Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000005236 alkanoylamino group Chemical group 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001356 alkyl thiols Chemical class 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 150000003857 carboxamides Chemical group 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 150000000921 Gadolinium Chemical class 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PFOLQBJDGRRJKE-UHFFFAOYSA-N [1,3]dioxolo[4,5-f][1,3]benzodioxole Chemical compound C1=C2OCOC2=CC2=C1OCO2 PFOLQBJDGRRJKE-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000004697 chelate complex Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- LYQGMALGKYWNIU-UHFFFAOYSA-K gadolinium(3+);triacetate Chemical compound [Gd+3].CC([O-])=O.CC([O-])=O.CC([O-])=O LYQGMALGKYWNIU-UHFFFAOYSA-K 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- WLKSZYPZGAQRKF-OCAPTIKFSA-N (1r,4s)-2,5-dimethylidenecyclohexane-1,4-diol Chemical compound O[C@H]1CC(=C)[C@H](O)CC1=C WLKSZYPZGAQRKF-OCAPTIKFSA-N 0.000 description 1
- PJXWCRXOPLGFLX-VIFPVBQESA-N (2s)-2-(benzylamino)propan-1-ol Chemical compound OC[C@H](C)NCC1=CC=CC=C1 PJXWCRXOPLGFLX-VIFPVBQESA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- FURLCQRFFWBENR-UHFFFAOYSA-N 1-benzyl-1,4,7,10-tetrazacyclododecane Chemical compound C=1C=CC=CC=1CN1CCNCCNCCNCC1 FURLCQRFFWBENR-UHFFFAOYSA-N 0.000 description 1
- MVAWRWBZHDXWSL-UHFFFAOYSA-N 1-benzyl-2-methylaziridine Chemical compound CC1CN1CC1=CC=CC=C1 MVAWRWBZHDXWSL-UHFFFAOYSA-N 0.000 description 1
- CASDNPHWJOQUQX-UHFFFAOYSA-N 1-benzylaziridine Chemical compound C=1C=CC=CC=1CN1CC1 CASDNPHWJOQUQX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WIRAXZLNWXIWDG-UHFFFAOYSA-N CCN(CC)NC(O)=O Chemical compound CCN(CC)NC(O)=O WIRAXZLNWXIWDG-UHFFFAOYSA-N 0.000 description 1
- CITIKIVKVRSHGW-UHFFFAOYSA-N CCOC(=O)C1CC(=O)C(CC1=O)C(=O)O Chemical compound CCOC(=O)C1CC(=O)C(CC1=O)C(=O)O CITIKIVKVRSHGW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UAQVHNZEONHPQG-ZETCQYMHSA-N N-benzoyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)C1=CC=CC=C1 UAQVHNZEONHPQG-ZETCQYMHSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000010477 Prilezhaev reaction Methods 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ICSLPLTUQWNNFL-UHFFFAOYSA-N [N+](=O)([O-])NC=1C(=O)NC(C=1)=O Chemical compound [N+](=O)([O-])NC=1C(=O)NC(C=1)=O ICSLPLTUQWNNFL-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- ZYTLPUIDJRKAAM-UHFFFAOYSA-N benzyl 2-hydroxypropanoate Chemical compound CC(O)C(=O)OCC1=CC=CC=C1 ZYTLPUIDJRKAAM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical compound O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 description 1
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006115 defluorination reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical compound [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- ZPKMIURLGRBLPQ-UHFFFAOYSA-K gadolinium(3+);triacetate;tetrahydrate Chemical compound O.O.O.O.[Gd+3].CC([O-])=O.CC([O-])=O.CC([O-])=O ZPKMIURLGRBLPQ-UHFFFAOYSA-K 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical group C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229920003228 poly(4-vinyl pyridine) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Farming Of Fish And Shellfish (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記式Iで表される化合物又はそれらの塩若しくは多量体: 上式中、 各m、n、o及びpは独立に1又は2である; qは0又は1である; 各Gは独立に、−COOR”、−P(O)(OR”)2、−P(O)(OR” )(R”)又は−C(O)N(R”)2である; 各R’は独立に、水素、又は各々任意に置換されたアルキル、アルコキシ、シ クロアルキル、ヒドロキシアルキル若しくはアリールであるか、又は生体分子と の接合体若しくは上式Iで表される前記化合物の多量体を形成することができる 官能基である; 各R”は水素である; R13〜R20の各々は独立に、水素、アルキル、ヒドロキシアルキル、アルコキ シアルキルであるか、又は生体分子との接合体若しくは上式Iで表される前記化 合物の多量体を形成することができる官能基である; 又は、R13はR15と共に、及びR17はR18と共に、それらが結合 しているテトラアザシクロドデカン巨大環中の炭素原子とで完全若しくは部分的 に飽和の非芳香族シクロヘキシル縮合環を独立に形成しており、前記シクロヘキ シル縮合環が置換されていないか又は1個以上のハロゲン基、アルキル基、エー テル基、ヒドロキシ基若しくはヒドロキシアルキル基で置換されていてよく、更 に縮合して炭素環式環を形成していているか、又はR13及びR15がそれぞれ水素 であり、且つR17がR18と共に上記したような完全若しくは部分的に飽和の非芳 香族シクロヘキシル縮合環を形成しているか、又はR13がR15と共に上記したよ うな完全若しくは部分的に飽和の非芳香族シクロヘキシル縮合環を形成しており 、且つR17及びR18が水素である;但し、(a.)Gが常に−COOR”であり 、且つ、(i.)R’、R”、R14及びR16〜R20が全て水素である場合には、 R13及びR15は水素以外のものであり;(ii.)R”及びR13〜R20が全て水素 であり、且つm、n、o、p及びqが各々1である場合には、(CR’R’)は (CH2)及び(CHCH3)以外のものであり;(iii.)R’、R”、R13、 R14、R17及びR20が全て水素である場合には、R15、R16、R18及びR19の少 なくとも2種がメチル以外のものであり;及び(iv.)R”、R16、R19及びR20 が全て水素であり、各(CR'R’)が独立に(CHR’)又は(CHCHR ’)である場合には、R13、R15、R17及びR18は縮合環以外のものである;並 びに(b.)Gが常に−P(O)(OR”)2、−P(O)(OR”)(R”) 又は−C(O)N(R”)2である場合には、R’又はR13〜R20は水素以外の ものである。 2.金属原子と錯形成した請求項1記載の化合物を含んでなる金属キレート。 3.金属が原子番号21〜29、42又は57〜83の原子から選ばれる請求 項2記載のキレート。 4.前記金属がガドリニウムである請求項3記載のキレート。 5.下記式IIで表される化合物: 上式中、 Qは、完全又は部分的に飽和していてよい炭素環式4〜8員環である; tは2〜16の整数である; 各R基は独立に、水素、−OH、−CH2−A、−OCH2CH(OH)CH2 −Aであるか、又は生体分子と接合体を形成することができる官能基であるが、 少なくとも2個のR基は−CH2−A又は−OCH2CH(OH)CH2−Aから 選ばれる;並びに Aは金属原子をキレート化することができる部分である。 6.Aが、 であるか、又はこれらの塩若しくは多量体である請求項5記載の化合物: 上式中、 各m、n、o及びpは独立に1又は2である; qは0又は1である; 各Gは独立に、−COOR”、−P(O)(OR”)2、−P(O)(OR” )(R”)又は−C(O)N(R”)2である; 各R’は独立に、水素、又は各々任意に置換されたアルキル、アルコキシ、シ クロアルキル、ヒドロキシアルキル若しくはアリールであるか、又は生体分子と の接合体若しくは上式Iで表される前記化合物の多量体を形成することができる 官能基である; 各R”は水素である; R13〜R20の各々は独立に、水素、アルキル、ヒドロキシアルキル、アルコキ シアルキルであるか、又は生体分子との接合体若しくは上式Iで表される前記化 合物の多量体を形成することができる官能基である; 又は、R13はR15と共に、及びR17はR18と共に、それらが結合しているテト ラアザシクロドデカン巨大環中の炭素原子とで完全若しくは部分的に飽和の非芳 香族シクロヘキシル縮合環を独立に形成しており、前記シクロヘキシル縮合環は 未置換であるか又は1個以上のハロゲン基、アルキル基、エーテル基、ヒドロキ シ基若しくはヒドロキシアルキル基で置換されていてよく、更に縮合して炭素環 式環を形成しているか、又はR13及びR15がそれぞれ水素であり、且つR17がR18 と共に上記したような完全若しくは部分的に飽和の非芳香族シクロヘキシル縮 合環を形成しているか、又はR13がR15と共に上記したような完全若しくは部分 的に飽和の非芳香族シクロヘキシル縮合環を形成しており、且つR17及びR18が 水素である;但し、(a.)Gが常に−COOR”であり、且つ、(i.)R’ 、R”、R14及びR16〜R20が全て水素である場合には、R13及びR15は水素以 外のものであり;(ii.)R”及びR13〜R20が全て水素であり、且つm、n、 o、p及びqが各々1である場合には、 (CR’R’)は(CH2)及び(CHCH3)以外のものであり;(iii.)R ’、R”、R13、R14、R17及びR20が全て水素である場合には、R15、R16、 R18及びR19の少なくとも2種がメチル以外のものであり;及び(iv.)R”、 R16、R19及びR20が全て水素であり、各(CR’R’)が独立に(CHR’) 又は(CHCHR’)である場合には、R13、R15、R17及びR18は縮合環以外 のものである;並びに(b.)Gが常に−P(O)(OR”)2、−P(O)( OR”)(R”)又は−C(O)N(R”)2である場合には、R’又はR13〜 R20は水素以外のものである。 7.Aが、 である請求項5記載の化合物: 上式中、 各R’は独立に、水素、アルキル、アルコキシ、ヒドロキシアルキル、アリー ル、アラルキル又はアリールアルコキシであり; 各R”は水素であり;並びに 各nは1又は2である。 8. が、 である請求項5記載の化合物: 上式中、 R1〜R12基の各々は独立に、水素、−OH、−CH2−A、−OCH2CH( OH)CH2−Aであるか、又は生体分子と接合体を形成することができる官能 基である; R1〜R12のうちの少なくとも2種は、−CH2−A又は−OCH2CH(OH )CH2−Aから選ばれる; R8及びR9は一緒に、各Rは独立に水素若しくはアルキルである基−O−[C (RR)]−O−を更に形成しているか、又はR8及びR9は一緒に、 を形成していてよい。 9. が下式で表される化合物である請求項6記載の化合物: 上式中、 R1〜R12基の各々は独立に、水素、−OH、−CH2−A、−OCH2CH( OH)CH2−Aであるか、又は生体分子と接合体を形成することができる官能 基である; R1〜R12のうちの少なくとも2種は、−CH2−A又は−OCH2CH(OH )CH2−Aから選ばれる; R8及びR9は一緒に、各Rが独立に水素若しくはアルキルである基−O−[C (RR)]−O−を更に形成しているか、又はR8及びR9は一緒に、 を形成していてよい。 10. が、 である請求項7記載の化合物: 上式中、 R1〜R12基の各々は独立に、水素、−OH、−CH2−A、−OCH2CH( OH)CH2−Aであるか、又は生体分子と接合体を形成することができる官能 基である; R1〜R12のうちの少なくとも2種は、−CH2−A又は−OCH2CH(OH )CH2−Aから選ばれる; R8及びR9は一緒に、各Rが独立に水素若しくはアルキルである基−O−[C (RR)]−O−を更に形成しているか、又はR8及びR9は一緒に、 を形成していてよい。 11.金属原子と錯形成した請求項5記載の化合物を含んでなる金属キレート 。 12.金属原子と錯形成した請求項6記載の化合物を含んでなる金属キレート 。 13.生体分子と接合した請求項5記載の化合物を含んでなる接合体。 14.金属原子と錯形成した請求項13記載の接合体を含んでなる金属キレー ト。 15.金属と錯形成した請求項5記載の化合物をホストに投与する工程及び前 記ホストの診断用映像を得る工程とを含んでなる診断用映像法。 16.前記映像が磁気共鳴映像である請求項15記載の方法。 17.金属と錯形成した請求項13記載の接合体をホストに投与 する工程及び前記ホストの診断用映像を得る工程とを含んでなる診断用映像法。 18.以下の化合物からなる群より選ばれる化合物: (1α,2α,4β,5β)−10,10’−[(1,2,4,5−テトラヒ ドロキシ−1,4−シクロヘキサンジイル)ビス(メチレン)]ビス[1,4, 7,10−テトラアザシクロドデカン−1,4,7−三酢酸]; (3aα,4α,5β,6α,7β,7aα)−10,10’,10’’,1 0’’’−[[ヘキサヒドロ−2,2−ジメチル−1,3−ベンゾジオキソール −4,5,6,7−テトライル]テトラ(オキシ)テトラ(2−ヒドロキシ−3 ,1−プロパンジイル)]テトラキス[1,4,7,10−テトラアザシクロド デカン−1,4,7−三酢酸]; 3,4,5,6−テトラ−O−[2−ヒドロキシ−3−[4,7,10−トリ ス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1− イル]プロピル]−ミオ−イノシトール; (1α,2α,3α,4β,5α,6β)−10,10’−[(2,3,5, 6−テトラヒドロキシ−1,4−シクロヘキサンジイル)ビス(2−ヒドロキシ −3,1−プロパンジイル)]ビス[1,4,7,10−テトラアザシクロドデ カン−1,4,7−三酢酸]; 10−[[1,4−ジヒドロキシ−2,5−ビス[2−ヒドロキシ−3−[4 ,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシク ロドデカン−1−イル]−プロポキシ]−4−[[4,7,10−トリス(カル ボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル]メ チル]シクロヘキシル]メチル]−1,4,7,10−テトラアザシクロドデカ ン−1,4,7−三酢酸; [3aR−(3aα,3”aα,4β,4”β,5α,5”α,6β,6”b ,7α,7”α,7aα,7”aα)]−ドデカヒドロ−4,4”,5,5”, 6,6”,7,7”−オクタキス−[[2−ヒドロキシ−3−[(4,7,10 −トリカルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1 −イル]プロピル]オキシ]ジスピロ−[1,3−ベンゾジオキソール−2,1 ’−シクロ−ヘキサン−4’,2”−[1,3]−ベンゾジオキソール]; [2S−(2α,5α,8α,11α)]−2,5,8,11−テトラメチル −1,4,7,10−テトラアザシクロドデカン−1,4,7,10−四酢酸; [αR−(aR*,α’R*,α’’R*,α’’’R*,2S*,5S*,8S* ,11S*)]−α,α’,α’’,a’’’,2,5,8,11−オクタメチ ル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−四酢酸 ; [2S−(2R*,5R*,8R*,11R*)]−2,5,8,11−テトラメ チル−1,4,7,10−テトラアザシクロドデカン−1,4,7−三酢酸; 10−(ホスホノメチル)−1,4,7,10−テトラアザシクロドデカン− 1,4,7−三酢酸。 19.以下の化合物からなる群より選ばれる化合物: (1α,2α,4β,5β)−10,10’−[(1,2,4,5−テトラヒ ドロキシ−1,4−シクロヘキサンジイル)ビス(メチレン)]ビス[1,4, 7,10−テトラアザシクロドデカン−1,4,7−三酢酸]二ガドリニウム塩 ; (3aα,4α,5β,6α,7β,7aα)−10,10’, 10’’,10’’’−[[ヘキサヒドロ−2,2−ジメチル−1,3−ベンゾ ジオキソール−4,5,6,7−テトライル]テトラ(オキシ)テトラ(2−ヒ ドロキシ−3,1−プロパンジイル)]テトラキス[1,4,7,10−テトラ アザシクロドデカン−1,4,7−三酢酸]四ガドリニウム塩; 3,4,5,6−テトラ−O−[2−ヒドロキシ−3−[4,7,10−トリ ス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1− イル]プロピル]−ミオ−イノシトール四ガドリニウム塩; (1α,2α,3α,4β,5α,6β)−10,10’−[(2,3,5, 6−テトラヒドロキシ−1,4−シクロヘキサンジイル)ビス(2−ヒドロキシ −3,1−プロパンジイル)]ビス[1,4,7,10−テトラアザシクロドデ カン−1,4,7−三酢酸]二ガドリニウム塩; 10−[[1,4−ジヒドロキシ−2,5−ビス[2−ヒドロキシ−3−[4 ,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシク ロドデカン−1−イル]−プロポキシ]−4−[[4,7,10−トリス(カル ボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル]メ チル]シクロヘキシル]メチル]−1,4,7,10−テトラアザシクロドデカ ン−1,4,7−三酢酸四ガドリニウム塩; [3aR−(3aα,3”aα,4β,4”β,5α,5”α,6β,6”b ,7α,7”α,7aα,7”aα)]−ドデカヒドロ−4,4”,5,5”, 6,6”,7,7”−オクタキス−[[2−ヒドロキシ−3−[(4,7,10 −トリカルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1 −イル]プロピル]オキシ]ジスピロ−[1,3−ベンゾジオキソール−2, 1’−シクロ−ヘキサン−4’,2”−[1,3]−ベンゾジオキソール]八ガ ドリニウム塩; [2S−(2α,5α,8α,11α)]−2,5,8,11−テトラメチル −1,4,7,10−テトラアザシクロドデカン−1,4,7,10−四酢酸ガ ドリニウム塩; [αR−(aR*,α’R*,α’’R*,α’’’R*,2S*,5S*,8S* ,11S*)]−α,α’,α’’,a’’’,2,5,8,11−オクタメチ ル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−四酢酸 ガドリニウム塩; [2S−(2R*,5R*,8R*,11R*)]−2,5,8,11−テトラメ チル−1,4,7,10−テトラアザシクロドデカン−1,4,7−三酢酸ガド リニウム塩; 10−(ホスホノメチル)−1,4,7,10−テトラアザシクロドデカン− 1,4,7−三酢酸ガドリニウム塩。 20.[1R−(1R*,4R*,7R*,10R*)]−α,α’,α’’,α ’’’−テトラメチル−1,4,7,10−テトラアザシクロドデカン−1,4 ,7,10−四酢酸又は[1R−(1R*,4R*,7R*)]−α,α’,α’ ’−トリメチル−1,4,7,10−テトラアザシクロドデカン−1,4,7− 三酢酸以外の、1015M-1を超える安定度を有し、且つ約60〜200mM-1s-1 /金属原子の固定化緩和度(immobilized relaxivity)を示すことができるキ レート。 21.約70〜150mM-1s-1/金属原子の固定化緩和度を示すことができ る請求項20記載のキレート。 22.約80〜100mM-1s-1/金属原子の固定化緩和度を示すことができ る請求項20記載のキレート。 23.1015M-1を超える安定度を有し、且つ約60〜200m M-1s-1/金属原子の固定化緩和度を示すことができる、請求項1記載の化合物 を含んでなるキレート。 24.1015M-1を超える安定度を有し、且つ約70〜150mM-1s-1/金 属原子の固定化緩和度を示すことができる、請求項1記載の化合物を含んでなる キレート。 25.1015M-1を超える安定度を有し、且つ約80〜100mM-1s-1/金 属原子の固定化緩和度を示すことができる、請求項1記載の化合物を含んでなる キレート。 26.1015M-1を超える安定度を有し、且つ約60〜200mM-1s-1/金 属原子の固定化緩和度を示すことができる、請求項8記載の化合物を含んでなる キレート。 27.1015M-1を超える安定度を有し、且つ約70〜150mM-1s-1/金 属原子の固定化緩和度を示すことができる、請求項8記載の化合物を含んでなる キレート。 28.1015M-1を超える安定度を有し、且つ約80〜100mM-1s-1/金 属原子の固定化緩和度を示すことができる、請求項8記載の化合物を含んでなる キレート。 29.[1R−(1R*,4R*,7R*,10R*)]−α,α’,α’’,α ’’’−テトラメチル−1,4,7,10−テトラアザシクロドデカン−1,4 ,7,10−四酢酸又は[1R−(1R*,4R*,7R*)]−α,α’,α’ ’−トリメチル−1,4,7,10−テトラアザシクロドデカン−1,4,7− 三酢酸以外の、約60〜200mM-1s-1/金属原子の固定化緩和度を示すこと ができる固定化官能基(immobilized functional group) を含むキレート。 30.約70〜150mM-1s-1/金属原子の固定化緩和度を示すことができ る請求項29記載のキレート。 31.約80〜100mM-1s-1/金属原子の固定化緩和度を示すことができ る請求項29記載のキレート。 32.請求項1記載の化合物を含んでなり、約60〜200mM-1s-1/金属 原子の固定化緩和度を示すことができる官能基を含むキレート。 33.請求項1記載の化合物を含んでなり、約70〜150mM-1s-1/金属 原子の固定化緩和度を示すことができる官能基を含むキレート。 34.請求項1記載の化合物を含んでなり、約80〜100mM-1s-1/金属 原子の固定化緩和度を示すことができる官能基を含むキレート。 35.請求項8記載の化合物を含んでなり、約60〜200mM-1s-1/金属 原子の固定化緩和度を示すことができる官能基を含むキレート。 36.請求項8記載の化合物を含んでなり、約70〜150mM-1s-1/金属 原子の固定化緩和度を示すことができる官能基を含むキレート。 37.請求項8記載の化合物を含んでなり、約80〜100mM-1s-1/金属 原子の固定化緩和度を示すことができる、官能基を含むキレート。 38.[1R−(1R*,4R*,7R*,10R*)]−α,α’,α’’,α ’’’−テトラメチル−1,4,7,10−テトラアザシクロドデカン−1,4 ,7,10−四酢酸以外の、約60〜200mM-1s-1/金属原子の固定化緩和 度を示すことができる生体分子と接合したキレート。 39.約70〜150mM-1s-1/金属原子の固定化緩和度を示すことができ る請求項38記載のキレート。 40.約80〜100mM-1s-1/金属原子の固定化緩和度を示すことができ る請求項38記載のキレート。 41.請求項1記載の化合物を含んでなり、約60〜200mM-1s-1/金属 原子の固定化緩和度を示すことができる、生体分子に接合したキレート。 42.請求項1記載の化合物を含んでなり、約70〜150mM-1s-1/金属 原子の固定化緩和度を示すことができる、生体分子に接合したキレート。 43.請求項1記載の化合物を含んでなり、約80〜100mM-1s-1/金属 原子の固定化緩和度を示すことができる、生体分子に接合したキレート。 44.請求項8記載の化合物を含んでなり、約60〜200mM-1s-1/金属 原子の固定化緩和度を示すことができる、生体分子に接合したキレート。 45.請求項8記載の化合物を含んでなり、約70〜150mM-1s-1/金属 原子の固定化緩和度を示すことができる、生体分子に接合したキレート。 46.請求項8記載の化合物を含んでなり、約80〜100mM-1s-1/金属 原子の固定化緩和度を示すことができる、生体分子に接合したキレート。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/241,253 | 1994-05-11 | ||
US08/241,253 US6693190B1 (en) | 1994-05-11 | 1994-05-11 | Enhanced relaxivity monomeric and multimeric compounds |
PCT/IB1995/000337 WO1995031444A1 (en) | 1994-05-11 | 1995-05-09 | Enhanced relaxivity monomeric and multimeric compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09500660A true JPH09500660A (ja) | 1997-01-21 |
Family
ID=22909910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7529486A Pending JPH09500660A (ja) | 1994-05-11 | 1995-05-09 | 高緩和性単量体化合物及び多量体化合物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US6693190B1 (ja) |
EP (1) | EP0708761B1 (ja) |
JP (1) | JPH09500660A (ja) |
KR (1) | KR960703874A (ja) |
CN (1) | CN1128534A (ja) |
AT (1) | ATE222244T1 (ja) |
CA (1) | CA2164944A1 (ja) |
CZ (1) | CZ8596A3 (ja) |
DE (1) | DE69527759T2 (ja) |
NO (1) | NO306722B1 (ja) |
WO (1) | WO1995031444A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005504745A (ja) * | 2001-07-20 | 2005-02-17 | シエーリング アクチエンゲゼルシヤフト | 大環状金属錯体及び生体分子との結合体の製造のためのその使用 |
JP2008539223A (ja) * | 2005-04-26 | 2008-11-13 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Cest活性な常磁性の錯体を含むmri造影剤 |
JP2012162540A (ja) * | 2004-08-05 | 2012-08-30 | Johann Wolfgang Goethe-Univ Frankfurt Am Main | 標的分子の改変および組織化のための多価キレーター |
US9606114B2 (en) | 2004-08-05 | 2017-03-28 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Multivalent chelators containing a scaffold structure for modifying and organizing of target molecules |
JP2019529439A (ja) * | 2016-09-19 | 2019-10-17 | ザ ホンコン ポリテクニック ユニヴァーシティー | キラルなサイクレン化合物およびその使用 |
JP2020513402A (ja) * | 2016-11-28 | 2020-05-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770261B2 (en) | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US6713045B1 (en) | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
DE19608307C1 (de) * | 1996-02-26 | 1997-08-28 | Schering Ag | Verfahren zur Herstellung von 1,4,7,10-Tetraazacyclododecan und dessen Derivaten |
US5744616A (en) * | 1996-02-26 | 1998-04-28 | Schering Aktiengesellschaft | Process for the production of 1,4,7,10-tetraazacyclododecane and its derivatives |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US5900228A (en) | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US6713046B1 (en) | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
WO1999025389A2 (en) * | 1997-11-17 | 1999-05-27 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
US6565828B2 (en) * | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
US6656450B2 (en) | 2000-07-17 | 2003-12-02 | California Institute Of Technology, Inc. | Macrocyclic magnetic resonance imaging contrast agents |
AU2002211517A1 (en) | 2000-10-04 | 2002-04-15 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
EP1406879A1 (en) * | 2001-07-17 | 2004-04-14 | Therpharm GmbH | Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |
DE10135355C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
WO2003024388A2 (en) | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
CA2495442C (en) | 2002-09-06 | 2013-12-10 | Martin W. Brechbiel | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
EP1581794B1 (en) | 2003-01-10 | 2008-09-17 | Millennium Pharmaceuticals, Inc. | Method of determining risk for prostate cancer recurrence |
WO2005003105A1 (en) * | 2003-07-08 | 2005-01-13 | The University Of Hong Kong | Synthesis of tris n-alkylated 1,4,7,10-tetraazacyclododecanes |
US7012140B1 (en) * | 2003-07-14 | 2006-03-14 | Board Of Regents, The University Of Texas System | Selection of coordination geometry to adjust water exchange rates of paramagnetic metal ion-based macrocyclic contrast agents |
WO2005062828A2 (en) * | 2003-12-23 | 2005-07-14 | Bracco Imaging S.P.A. | New compounds useful as metal chelators |
CN1993629B (zh) * | 2004-07-29 | 2010-09-15 | 大塚制药株式会社 | 固体试料的核磁共振测定方法 |
WO2006045546A1 (en) * | 2004-10-20 | 2006-05-04 | Therapharm Gmbh | Method of preparing or synthesizing polyazamacrocycle derivatives |
CN101845112B (zh) * | 2010-06-02 | 2011-09-14 | 华东理工大学 | 一种基于高分子纳米粒子的高灵敏性核磁共振成像造影剂的制备方法 |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
CA3120665A1 (en) | 2018-11-23 | 2020-05-28 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3129906C3 (de) | 1981-07-24 | 1996-12-19 | Schering Ag | Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik |
SE465907B (sv) | 1984-11-01 | 1991-11-18 | Nyegaard & Co As | Diagnosticeringsmedel innehaallande en paramagnetisk metall |
US4880008A (en) | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
US4899755A (en) | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
US4678667A (en) | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
US5271927A (en) | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
DE3625417C2 (de) | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
IT1224416B (it) | 1987-12-24 | 1990-10-04 | Bracco Ind Chimica Spa | Chelanti macrociclici e loro chelati |
US5049667A (en) | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
FR2637895B1 (fr) | 1988-10-14 | 1992-11-06 | Guerbet Sa | Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands |
EP0466200B1 (en) | 1987-07-16 | 1996-04-24 | Nycomed Imaging As | Aminocarboxylic acids and derivatives thereof |
GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
WO1989011475A1 (en) | 1988-05-25 | 1989-11-30 | The United States Of America, As Represented By Th | Macrocyclic chelates and methods of use thereof |
US4923985A (en) | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
DE353450T1 (de) | 1988-06-24 | 1990-09-06 | The Dow Chemical Co., Midland, Mich. | Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikoerper. |
BR8907282A (pt) | 1988-12-23 | 1991-03-12 | Dow Chemical Co | Processo para preparar complexos de metal funcionalizados com isotiocianato |
DE69024826T2 (de) | 1989-02-10 | 1996-06-27 | Celltech Therapeutics Ltd | Aza-Macrozyklen und Verfahren zu deren Herstellung |
US5053503A (en) | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
DE3911816A1 (de) | 1989-04-11 | 1990-10-25 | Hoechst Ag | Substituierte 1,4,7,10-tetraazacyclotridecane, verfahren zu deren herstellung sowie verwendung derselben zur markierung von substanzen mit radionukliden |
IT1243801B (it) | 1990-08-29 | 1994-06-28 | Bracco Ind Chimica Spa | Intermedi per agenti chelanti con simmetria prefissata, e procedimentoper la loro preparazione |
US5162109A (en) | 1990-09-13 | 1992-11-10 | Mallinckrodt Medical, Inc. | Magnetic resonance imaging agents |
JPH04154729A (ja) | 1990-10-16 | 1992-05-27 | Nippon Mejifuijitsukusu Kk | 磁気共鳴造影剤 |
DE4035760A1 (de) | 1990-11-08 | 1992-05-14 | Schering Ag | Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
JPH06502858A (ja) | 1990-11-21 | 1994-03-31 | マリンクロッド・メディカル・インコーポレイテッド | 磁気共鳴イメージング用錯体および組成物,並びにこれらの使用法 |
FR2672051B1 (fr) | 1991-01-24 | 1993-05-21 | Guerbet Sa | Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique. |
GB9115375D0 (en) | 1991-07-17 | 1991-09-04 | Salutar Inc | Compounds |
EP0565930A1 (en) | 1992-03-27 | 1993-10-20 | Nihon Medi-Physics Co., Ltd. | Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents |
US6120768A (en) * | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
-
1994
- 1994-05-11 US US08/241,253 patent/US6693190B1/en not_active Expired - Fee Related
-
1995
- 1995-05-09 KR KR1019960700111A patent/KR960703874A/ko not_active Application Discontinuation
- 1995-05-09 CZ CZ9685A patent/CZ8596A3/cs unknown
- 1995-05-09 DE DE69527759T patent/DE69527759T2/de not_active Expired - Fee Related
- 1995-05-09 EP EP95915988A patent/EP0708761B1/en not_active Expired - Lifetime
- 1995-05-09 WO PCT/IB1995/000337 patent/WO1995031444A1/en active IP Right Grant
- 1995-05-09 CA CA002164944A patent/CA2164944A1/en not_active Abandoned
- 1995-05-09 JP JP7529486A patent/JPH09500660A/ja active Pending
- 1995-05-09 AT AT95915988T patent/ATE222244T1/de not_active IP Right Cessation
- 1995-05-09 CN CN95190415A patent/CN1128534A/zh active Pending
-
1996
- 1996-01-10 NO NO960115A patent/NO306722B1/no not_active IP Right Cessation
-
2003
- 2003-12-19 US US10/741,872 patent/US20040131551A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005504745A (ja) * | 2001-07-20 | 2005-02-17 | シエーリング アクチエンゲゼルシヤフト | 大環状金属錯体及び生体分子との結合体の製造のためのその使用 |
JP2012162540A (ja) * | 2004-08-05 | 2012-08-30 | Johann Wolfgang Goethe-Univ Frankfurt Am Main | 標的分子の改変および組織化のための多価キレーター |
US9606114B2 (en) | 2004-08-05 | 2017-03-28 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Multivalent chelators containing a scaffold structure for modifying and organizing of target molecules |
JP2008539223A (ja) * | 2005-04-26 | 2008-11-13 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Cest活性な常磁性の錯体を含むmri造影剤 |
JP2019529439A (ja) * | 2016-09-19 | 2019-10-17 | ザ ホンコン ポリテクニック ユニヴァーシティー | キラルなサイクレン化合物およびその使用 |
JP2020513402A (ja) * | 2016-11-28 | 2020-05-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物 |
Also Published As
Publication number | Publication date |
---|---|
KR960703874A (ko) | 1996-08-31 |
EP0708761B1 (en) | 2002-08-14 |
DE69527759D1 (de) | 2002-09-19 |
CA2164944A1 (en) | 1995-11-23 |
NO960115L (no) | 1996-03-05 |
US20040131551A1 (en) | 2004-07-08 |
NO960115D0 (no) | 1996-01-10 |
DE69527759T2 (de) | 2003-04-10 |
US6693190B1 (en) | 2004-02-17 |
WO1995031444A1 (en) | 1995-11-23 |
CN1128534A (zh) | 1996-08-07 |
ATE222244T1 (de) | 2002-08-15 |
EP0708761A1 (en) | 1996-05-01 |
CZ8596A3 (en) | 1996-06-12 |
NO306722B1 (no) | 1999-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09500660A (ja) | 高緩和性単量体化合物及び多量体化合物 | |
US5480990A (en) | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents | |
US5750660A (en) | Bicyclopolyazamacrocyclophosphonic acid half esters | |
JP3228296B2 (ja) | β,β’−ジヒドロキシメソ置換クロリン、イソバクテリオクロリン、バクテリオクロリン、およびβ,β’−非置換テトラピロールマクロサイクルからのそれらの製造方法 | |
JP3878208B2 (ja) | 芳香族アミド化合物およびそれらのキレート | |
EP0711300B1 (en) | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents | |
CN108368067B (zh) | 二聚造影剂 | |
JP4689775B2 (ja) | 低毒性の常磁性金属のキレート錯体 | |
Platzek et al. | Synthesis and structure of a new macrocyclic polyhydroxylated gadolinium chelate used as a contrast agent for magnetic resonance imaging | |
HU198501B (en) | Process for producing metal complexes of nitrogen-containing cyclic ligands and diagnostic compositions comprising such complexes | |
CN108779082B (zh) | 造影剂 | |
KR20190091441A (ko) | 다이머 조영제 | |
AU783640B2 (en) | Improvements in and relating to chromophores | |
RU2114115C1 (ru) | Производные бициклополиазамакроциклофосфоновых кислот или их фармацевтически приемлемые соли и способ их получения | |
US20080275232A1 (en) | Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy | |
AU2006272025A1 (en) | Complexes containing perfluoroalkyl, method for the production and use thereof | |
HUT67602A (en) | Process for producing bicyclo-polyaza-macrocyclo-carboxylic acid complexes, their conjugates and contrast materials containing them | |
EP3959208B1 (en) | Cyclen based compounds, coordination compounds, peptides, pharmaceutical preparation, and use thereof | |
US7582280B2 (en) | Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications | |
US20030203888A1 (en) | Chromophores | |
JPH08509976A (ja) | コントラスト剤として使用するためのビシクロポリアザマクロシクロホスホン酸、それらの錯体および複合体ならびにそれらの製造方法 | |
JPH03197468A (ja) | 二官能性大環状キレート配位子およびその製造法 | |
WO1994026313A1 (en) | Bicyclopolyazamacrocyclocarboxylic acid complexes, their conjugates, processes for their preparation, and use as contrast agents | |
KR100306331B1 (ko) | 비사이클로폴리아자매크로사이클로카복실산착체,그의결합체,그의제조방법및조영제로서의그의용도 | |
AU4237993A (en) | Bicyclopolyazamacrocyclocarboxylic acid complexes, their conjugates, processes for their preparation, and use as contrast agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070123 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090706 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091201 |